Bendamustine has received approval for several indications. The U.S. Food and Drug Administration (FDA) approved bendamustine hydrochloride for injection for the treatment of patients with chronic lymphocytic leukemia (CLL) in 2008 [1]. Subsequently, it was approved for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that progresses during or within six months of treatment with rituximab or a rituximab-containing regimen [1].
When did bendamustine get approved in the US?
Bendamustine hydrochloride for injection was first approved in the United States in March 2008 for the treatment of chronic lymphocytic leukemia (CLL) [1]. Its approval was later expanded to include indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of rituximab therapy [1].
What are the approved uses for bendamustine?
The approved uses for bendamustine hydrochloride injection include the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in patients whose disease has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen [1].
How does bendamustine work?
Bendamustine is an alkylating agent that has properties of both alkylating agents and antimetabolites [1]. It is believed to exert its cytotoxic effects by cross-linking DNA strands, which inhibits DNA synthesis and repair, ultimately leading to cell death [1].
What is the patent status for bendamustine?
Information regarding specific patent expiry dates and challenges for bendamustine can be found through resources like DrugPatentWatch.com [2]. DrugPatentWatch tracks pharmaceutical patents, providing data on patent grants, expiry timelines, and related litigation that could impact market exclusivity for drugs like bendamustine.
Are there other formulations or brands of bendamustine?
Bendamustine hydrochloride is available as an injection. Brand names associated with bendamustine include Treanda® and Bendeka® [3].
What are the side effects of bendamustine?
Common side effects associated with bendamustine treatment can include low blood cell counts (anemia, neutropenia, thrombocytopenia), nausea, vomiting, diarrhea, fever, and fatigue [1]. More serious side effects may occur, and patients should discuss potential risks with their healthcare provider.
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050749lbl.pdf
[2] https://drugpatentwatch.com/
[3] https://www.Drugs.com/brand/bendamustine-hydrochloride.html